The only way to get our innovative therapies to the patients that need them is to commercialize.
New york, ny
Bond Biosciences, Inc. develops non-absorbed and non-systemic chelators for treatment of iron overload disorders.
Exodus Biosciences, LLC is pioneering a biomaterial for the selective capture and amplification of rare immune cells. This technology is designed to enhance the diagnosis and treatment of autoimmune diseases like Multiple Sclerosis.
Orbis Biosciences develops oral and injectable pharmaceutical products for improved compliance. Their proprietary technologies provide customized drug release, format and dose flexibility, and taste-masking for oral drugs.
Orion Bioscience Inc. is a Nebraska biotechnology company developing innovative therapies to provide both immediate relief and long-term solutions to devastating autoimmune diseases.
Savara Pharmaceuticals’ lead product candidate is AeroVanc™ (vancomycin hydrochloride inhalation powder), the first inhaled antibiotic being developed to address the growing population of MRSA-infected cystic fibrosis patients. By delivering vancomycin directly to the site of infection, AeroVanc has the ability to improve clinical efficacy and reduce adverse effects caused by broad-spectrum antibiotics.